Marinus Pharmaceuticals, Inc. increased earnings guidance for full year 2024. For the year, company projected U.S. ZTALMY net product revenues to between $33 and $35 million from a range of $32 Million and $34 Million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.445 USD | -2.36% | -3.67% | -86.71% |
May. 17 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
May. 17 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.71% | 79.1M | |
+42.83% | 750B | |
+34.11% | 606B | |
-5.70% | 356B | |
+18.06% | 326B | |
+4.63% | 286B | |
+18.36% | 246B | |
-2.86% | 213B | |
+11.10% | 213B | |
+2.43% | 167B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024